Short interest for OraSure Technologies gives investors a sense of the degree to which investors are betting on the decline of OraSure Technologies's stock. Short interest data is updated every two weeks.

OraSure Technologies Stock (NASDAQ:OSUR), Short Interest Report

OraSure Technologies

OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

News

Short Ideas

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

DOCS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NTRA

OSUR

As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 5 Health Care Stocks That May Collapse In November

Government

Health Care

General

BRKR

TSX:CEMI

CODX

EXAS

TSX:FLDM

HOLX

Laboratory Corporation Of America Holdings

LMDX

QDEL

QGEN

RHHBF

RHHBY

RHHVF

TWST

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year

Penny Stocks

Intraday Update

Movers

AAOI

AAPL

ABCL

ALEC

ALHC

AMCX

AMRX

AMZN

ASRT

ATRO

ATSG

BIGC

BJDX

CARG

DKNG

DOCN

FTNT

GMBL

INVE

INVO

IRTC

KTOS

LASR

LSXMA

MCHP

MESO

MODV

OLED

OPEN

PANW

PRDO

RDFN

REZI

TEAM

TKAT

TMDX

TMPO

TRIN

TRUP

WISH

YELL

Gainers


	Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition.


Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

OraSure Technologies, Inc. - Common Stock

OraSure Technologies Inc

<p>Evercore ISI Group  analyst Vijay Kumar   maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a In-Line and lowers the price target from $7 to $6.5.</p>


Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on OraSure Technologies, Lowers Price Target to $6.5

WIIM

OraSure Technologies shares are trading higher after the company reported better-than-expected Q4 financial results.

<p><strong>OraSure Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>OraSure Technologies beat estimated earnings by 175.0%, reporting an EPS of $0.22 versus an estimate of $0.08.</p>
<p>Revenue was down $47.20 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.23 which was followed by a 3.0% increase in the share price the next day.</p>
<p>Here's a look at OraSure Technologies's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.04</td>
<td>-0.08</td>
<td>0.14</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.09</td>
<td>0.47</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>74.96M</td>
<td>63.86M</td>
<td>126.57M</td>
<td>97.10M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>89.19M</td>
<td>85.44M</td>
<td>154.96M</td>
<td>123.08M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for OraSure Technologies <a href="https://www.benzinga.com/quote/OSUR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

OraSure Technologies: Q4 Earnings Insights

<p>OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.09 by 144.44 percent.  The company reported quarterly sales of $75.88 million which beat the analyst consensus estimate of $74.12 million by 2.38 percent.  This is a 38.35 percent decrease over sales of $123.08 million the same period last year.</p>


Earnings Beats

OraSure Technologies Q4 2023 Adj EPS $0.22 Beats $0.09 Estimate, Sales $75.88M Beat $74.12M Estimate

ACAD

ACHC

AESI

AHCO

AIRS

AMBA

AMBC

APLS

ARKO

ARQT

ARRY

ATEC

AXON

BCSF

BECN

BGFV

BMBL

BWXT

BYND

CAVA

CBRL

CIVI

CLDT

CLNE

CLVT

CMLS

COMP

CPNG

CRDO

CYTK

EBAY

EHTH

ESPR

FARO

FLYW

FOUR

FSLR

FULC

GDOT

GLPI

GMRE

GSX Techedu Inc. American Depositary Shares

GOTU

GPOR

HRZN

HSIC

HURN

ICCC

ICFI

ICUI

IMAX

IMXI

INGN

INSE

IPAR

JAMF

KIND

KURA

KVYO

LAZR

LGND

LGVN

Earnings Scheduled For February 27, 2024

<p><strong>OraSure Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-27. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that OraSure Technologies will report an <strong>earnings per share</strong> (EPS) of $0.08. </p>
<p>OraSure Technologies bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.23, which was followed by a 2.87% increase in the share price the next day.</p>
<p>Here's a look at OraSure Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2023</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.04</td>
<td>-0.08</td>
<td>0.14</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.09</td>
<td>0.47</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>32.0%</td>
<td>5.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1708963313_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of OraSure Technologies were trading at $6.96 as of February 23. Over the last 52-week period, shares are up 10.38%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/OSUR/earnings"><strong>To track all earnings releases for OraSure Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: OraSure Technologies's Earnings

Contracts

OraSure Technologies Announced It Is Leading The Series B Financing And Has Penned Wide-ranging Strategic Distribution Deals With Sapphiros And Certain Of Its Related Entities

<p>Citigroup  analyst Patrick Donnelly   maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a Buy and raises the price target from $7 to $9.</p>


Citigroup Maintains Buy on OraSure Technologies, Raises Price Target to $9

<p>As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.</p>
<p>The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.</p>
<p>Here&rsquo;s the latest list of major overbought players in this sector.</p>
<h3><strong>OraSure Technologies, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/osur#NASDAQ">OSUR</a>)</h3>
<ul>
<li>OraSure Technologies posted upbeat quarterly results. &ldquo;We continue to make progress on our transformation journey by &lsquo;innovating and operating with disciplined execution and accountability&rsquo;. During the third quarter, we generated significant positive operating cash flow with margin expansion, driven by our enterprise-wide focus on operational efficiency,&rdquo; said OraSure President and CEO Carrie Eglinton Manner. The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/OSUR"><em>52-week high of $7.82. </em></a>.</li>
<li><strong>RSI Value:</strong> 77.78</li>
<li><strong>OSUR Price Action: </strong> Shares of OraSure Technologies fell 0.6% to close at $6.90 on Thursday.</li>
</ul>
<h3><strong>POINT Biopharma Global Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pnt#NASDAQ">PNT</a>)</h3>
<ul>
<li>The company posted net loss of $24.8 million, or $0.23 per share, for the three months ended Sept. 30, 2023. &ldquo;The founding mission of our company is to accelerate the discovery, development and global access to radiopharmaceuticals,&rdquo; said Joe McCann, Ph.D., CEO of POINT Biopharma. &ldquo;I view Lilly&rsquo;s agreement to acquire POINT as validation of the uniqueness of our team, infrastructure and pipeline. Together, we can become a global radiopharmaceutical leader, executing on our mission and transforming lives touched by cancer.&quot; The company&rsquo;s <a href="https://www.benzinga.com/quote/PNT"><em> stock has a 52-week high </em></a> of $13.55.</li>
<li><strong>RSI Value:</strong> 74.75</li>
<li><strong>PNT Price Action: </strong> Shares of POINT Biopharma Global fell 0.5% to close at $13.33 on Thursday.</li>
</ul>
<h3><strong>Natera, Inc. </strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntra#NASDAQ">NTRA</a>)</h3>
<ul>
<li>Natera has entered into an agreement with Merck, under which Merck will utilize Natera&#39;s real-world database to advance oncology research. The company has a <a href="https://www.benzinga.com/quote/NTRA"><em> 52-week high </em></a> of $63.00.</li>
<li><strong>RSI Value:</strong> 71.60</li>
<li><strong>NTRA Price Action: </strong> Shares of Natera fell 0.3% to close at $52.81 on Thursday.</li>
</ul>
<h3><strong>Doximity, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docs#NYSE">DOCS</a>)</h3>
<ul>
<li>Doximity reported better-than-expected second-quarter financial results and issued revenue guidance above estimates. &quot;We&rsquo;re proud to make medicine mobile, with another quarter of record engagement across our entire platform,&quot; said Jeff Tangney, co-founder and CEO of Doximity. The company&rsquo;s 52-week high is $40.12.</li>
<li><strong>RSI Value:</strong> 70.05</li>
<li><strong>DOCS Price Action: </strong> Shares of Doximity closed at $25.40 on Thursday.</li>
</ul>
<h3><strong>Hims &amp; Hers Health, Inc. </strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>)</h3>
<ul>
<li>Hims &amp; Hers reported better-than-expected third-quarter sales results, raised FY23 guidance above estimates and announced a $50 million share repurchase program. &quot;I am proud of the progress made across several of our key pillars in the third quarter which meaningfully moved Hims &amp; Hers one step closer toward our vision of an accessible, personalized platform,&quot; said Andrew Dudum, co-founder and CEO. The company <a href="https://www.benzinga.com/quote/HIMS"><em> has a 52-week high </em></a> of $12.34.</li>
<li><strong>RSI Value:</strong> 71.22</li>
<li><strong>HIMS Price Action: </strong> Shares of Hims &amp; Hers Health settled at $7.71 on Thursday.</li>
</ul>
<p>&nbsp;</p>
<p>Read More: <a href="https://www.benzinga.com/news/earnings/23/11/35843238/bjs-wholesale-club-gap-and-3-stocks-to-watch-heading-into-friday"><em> BJ&#39;s Wholesale Club, Gap And 3 Stocks To Watch Heading Into Friday </em></a></p>


<p>JP Morgan  analyst Tycho Peterson   maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a Neutral and lowers the price target from $6 to $5.</p>


JP Morgan Maintains Neutral on OraSure Technologies, Lowers Price Target to $5

<p><strong>Financial Guidance</strong></p>
<p>The Company is guiding to Q4 2023 revenue of $71 to $76 million, which includes core revenue of $33 to $35 million and InteliSwab&#xAE; revenue of $38 to $41 million. As part of our ongoing focus on enterprise-wide operating efficiency, the Company is on track to exceed the $15 million of annualized cost savings announced in Q1 2023.</p>
<p><br />&nbsp;</p>


Guidance

OraSure Technologies Sees Q4 Revenue $71M-$76M Vs $73.62M Est.

<p><strong>OraSure Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported its Q3 earnings results on Tuesday, November 7, 2023 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>OraSure Technologies beat estimated earnings by 575.0%, reporting an EPS of $0.27 versus an estimate of $0.04.</p>
<p>Revenue was down $27.28 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.17 which was followed by a 32.29% increase in the share price the next day.</p>
<p>Here's a look at OraSure Technologies's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2023</strong></th>
<th><strong>Q1 2023</strong></th>
<th><strong>Q4 2022</strong></th>
<th><strong>Q3 2022</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>0.14</td>
<td>-0.01</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.09</td>
<td>0.47</td>
<td>0.36</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>63.86M</td>
<td>126.57M</td>
<td>97.10M</td>
<td>91.71M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>85.44M</td>
<td>154.96M</td>
<td>123.08M</td>
<td>116.46M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for OraSure Technologies <a href="https://www.benzinga.com/quote/OSUR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: OraSure Technologies Q3 Earnings

<p>OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.04 by 575 percent. This is a 107.69 percent increase over earnings of $0.13 per share from the same period last year.  The company reported quarterly sales of $89.19 million which beat the analyst consensus estimate of $74.96 million by 18.98 percent.  This is a 23.42 percent decrease over sales of $116.46 million the same period last year.</p>


OraSure Technologies Q3 2023 Adj EPS $0.27 Beats $0.04 Estimate, Sales $89.19M Beat $74.96M Estimate

-

-

-

-

-

-

-

-

-

-

-

-

-

-

OraSure Technologies Stock (NASDAQ:OSUR), Short Interest Report

People Also Watch